US3683080A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
Assignee: Procter and Gamble Co
•
Filing: 1970-08-28
•
Granted: 1972-08-08
•
Expires: 1990-08-28
Abstract
Abstract Compositions for inhibiting anomalous deposition and mobilization of calcium phosphates in animal tissue, comprising an effective amount of certain polyphosphonates as herein defined, and a pharmaceutical carrier; and a method for treating or preventing conditions involving pathological calcification and hard tissue demineralization in an animal comprising administering to such animal said compositions.
Inventors
- 👤 Marion D Francis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 04:54
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/3804; C07F9/3839
Claims Analysis
Total Claims: 50
Claim 1
Independent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is methanehydroxydiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is ethane-1-amino-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is methanediphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is ethane-1-hydroxy-1,1,2-triphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is propane-1,2,3-triphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is butane-1,2,3,4-tetraphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is hexane-1,2,3,4,5,6-hexaphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is methanephenylaminodiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
15 words
The composition of claim 1 wherein the dosage unit form is adapted to oral administration.
Claim 10
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is methanedichlorodiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
27 words
The composition of claim 11 wherein the dosage unit form is adapted to oral administration and comprises from about 100 mg. to about 500 mg. of polyphosphonate.
Claim 12
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 13
Dependent Claim
27 words
The composition of claim 13 wherein the dosage unit form is adapted to oral administration and comprises from about 100 mg. to about 500 mg. of polyphosphonate.
Claim 14
Independent Claim
109 words
A method for inhibiting anomalous deposition or mobilization of calcium phosphates in animal tissue which comprises systemically administering to animals an effective but non-toxic amount of a polyphosphonate selected from the group consisting of wherein R1 and R2 are each hydrogen or CH2OH; n is an integer of from 3 to 10; R3 is hydrogen, alkyl containing from one to about 20 carbon atoms, alkenyl containing from two to about 20 carbon atoms, phenyl, naphthyl, phenylethenyl, benzyl, halogen, amino, substituted amino, -CH2COOH, -CH2PO3H2, -CH(PO3H2)(OH), or -CH2CH(PO3H2)2; R4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, -CH2COOH, -CH2PO3H2, or -CH2CH2PO3H2; and the pharmaceutically acceptable salts thereof, and a pharmaceutical carrier.
Claim 15
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is methanedichlorodiphosphonic acid.
Claim 16
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is ethane-1-hydroxy-1,1-diphosphonic acid.
Claim 17
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is methanehydroxydiphosphonic acid.
Claim 18
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is ethane-1-amino-1,1-diphosphonic acid.
Claim 19
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is methanediphosphonic acid.
Claim 20
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is ethane-1-hydroxy-1,1,1-triphosphonic acid.
Claim 21
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is propane-1,2,3-triphosphonic acid.
Claim 22
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is butane-1,2,3,4-tetraphosphonic acid.
Claim 23
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is hexane-1,2,3,4,5,6-hexaphosphonic acid.
Claim 24
Dependent Claim
11 words
The method of claim 15 wherein the polyphosphonate is methanephenylaminodiphosphonic acid.
Claim 25
Dependent Claim
96 words
An animal feed composition comprising (1) a minor proportion of a polyphosphonate selected from the group consisting of wherein R1 and R2 are each hydrogen or CH2OH; n is an integer from 3 to 10; R3 is hydrogen, alkyl containing from one to about 20 carbon atoms, alkenyl containing from two to about 20 carbon atoms, phenyl, naphthyl, phenylethenyl, benzyl, halogen, amino, substituted amino, -CH2COOH, -CH2PO3H2, -CH(PO3H2)(OH), or -CH2CH(PO3H2)2; R4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, -CH2COOH, -CH2PO3H2, or -CH2CH2PO3H2; and the pharmaceutically acceptable salts thereof, and (2) a major proportion of animal foodstuff.
Claim 26
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is methanedichlorodiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 27
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 28
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is methanehydroxydiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 29
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is ethane-1-amino-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 30
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is methanediphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 31
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is ethane-1-hydroxy-1,1,2-triphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 32
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is propane-1,2,3-triphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 33
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is butane-1,2,3,4-tetraphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 34
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is hexane-1,2,3,4,5,6-hexaphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 35
Dependent Claim
17 words
The composition of claim 26 wherein the polyphosphonate is methanephenylaminodiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 36
Independent Claim
99 words
A method for treating Paget''s disease comprising sYstemically administering to an animal afflicted therewith an effective but non-toxic amount of a polyphosphonate selected from the group consisting of wherein R1 and R2 are each hydrogen or CH2OH; n is an integer of from 3 to 10; R3 is hydrogen, alkyl containing from one to about 20 carbon atoms, alkenyl containing from two to about 20 carbon atoms, phenyl, naphthyl, phenylethenyl, benzyl, halogen, amino, substituted amino, -CH2COOH, -CH2PO3H2, -CH(PO3H2)(OH), or -CH2CH(PO3H2)2; R4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, -CH2COOH, -CH2PO3H2, or -CH2CH2PO3H2; and the pharmaceutically acceptable salts thereof.
Claim 37
Dependent Claim
17 words
The method of claim 37 wherein the polyphosphonate is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 38
Dependent Claim
17 words
The method of claim 37 wherein the polyphosphonate is methanedichlorodiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 39
Independent Claim
94 words
A method for treating osteoporosis comprising administering to an animal afflicted therewith an effective but non-toxic amount of polyphosphonate selected from the group consisting of wherein R1 and R2 are each hydrogen or CH2OH; n is an integer of from 3 to 10; R3 is hydrogen, alkyl containing from one to about 20 carbon atoms, alkenyl containing from two to about 20 carbon atoms, phenyl, naphthyl, phenylethenyl, benzyl, halogen, amino, substituted amino, -CH2COOH, -CH2PO3H2, -CH(PO3H2)(OH), or -CH2CH(PO3H2)2;R4is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, -CH2COOH, -CH2PO3H2, or -CH2CH2PO3H2; and the pharmaceutically acceptable salts thereof.
Claim 40
Dependent Claim
17 words
The method of claim 40 wherein the polyphosphonate is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 41
Dependent Claim
17 words
The method of claim 40 wherein the polyphosphonate is methanedichlorodiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 42
Independent Claim
95 words
A method for treating arthritis comprising administering to an animal afflicted therewith an effective but non-toxic amount of a polyphosphonate selected from the group consisting of wherein R1 and R2 are each hydrogen or CH2OH; n is an integer of from 3 to 10; R3 is hydrogen, alkyl containing from one to about 20 carbon atoms, alkenyl containing from two to about 20 carbon atoms, phenyl, naphthyl, phenylethenyl, benzyl, halogen, amino, substituted amino, -CH2COOH, -CH2PO3H2, -CH(PO3H2)(OH), or -CH2CH(PO3H2)2;R4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, -CH2COOH,-CH2PO3H2, or -CH2CH2PO3H2; and the pharmaceutically acceptable salts thereof.
Claim 43
Dependent Claim
17 words
The method of claim 43 wherein the polyphosphonate is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 44
Dependent Claim
17 words
The method of claim 43 wherein the polyphosphonate is methanedichlorodiphosphonic acid or a pharmaceutically acceptable salt hereof.
Claim 45
Independent Claim
97 words
A method for treating urolithiasis comprising administering to an animal afflicted therewith an effective but non-toxic amount of a polyphosphonate selected from the group consisting of wherein R1 and R2 are each hydrogen or CH2OH; n is an integer of from 3 to 10; R3 is hydrogen, alkyl Containing from one to about 20 carbon atoms, alkenyl containing from two to about 20 carbon atoms, phenyl, naphthyl, phenylethenyl, benzyl, halogen, amino, substituted amino, -CH2COOH, -CH2PO3H2, -CH(PO3H2)(OH), or -CH2CH(PO3H2)2; R4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, -CH2COOH, -CH2PO3H2, or -CH2CH2PO3H2; and the pharmaceutically acceptable salts thereof.
Claim 46
Dependent Claim
17 words
The method of claim 46 wherein the polyphosphonate is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 47
Dependent Claim
17 words
The method of claim 46 wherein the polyphosphonate is methanedichlorodiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 48
Independent Claim
97 words
A method for treating arteriosclerosis comprising administering to an animal afflicted therewith an effective but non-toxic amount of a polyphosphonate selected from the group consisting of wherein R1 and R2 are each hydrogen or CH2OH; n is an integer of from 3 to 10; R3 is hydrogen, alkyl containing from one to about 20 carbon atoms, alkenyl containing from two to about 20 carbon atoms, phenyl, naphthyl, phenylethenyl, benzyl, halogen, amino, substituted amino, -CH2COOH, -CH2PO3H2, -CH(PO3H2)(OH), or -CH2CH(PO3H2)2; R4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, -CH2COOH, -CH2PO3H2, or -CH2CH2PO3H2; and the pharmaceutically acceptable salts thereof.
Claim 49
Dependent Claim
17 words
The method of claim 49 wherein the polyphosphonate is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 50
Dependent Claim
17 words
The method of claim 49 wherein the polyphosphonate is methanedichlorodiphosphonic acid or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1975-08-08 | 1976-02-07 | 1976-08-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1979-08-08 | 1980-02-07 | 1980-08-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1983-08-08 | 1984-02-07 | 1984-08-08 | $7700.00 | Window Closed / Lapsed |